GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025.
Previous
Previous
CLSP-5282, a first-in-class T cell engager targeting KRasG12V mutant peptide presented on HLA-A*03:01
Next
Next